Effect of Eurycoma longifolia standardised aqueous root extract–Physta® on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study
Open Access
- 19 May 2021
- journal article
- research article
- Published by SNF Swedish Nutrition Foundation in Food & Nutrition Research
Abstract
Background: Low testosterone levels cause physiological changes that compromise the quality of life in ageing men. A standardised water extract from the root of Eurycoma longifolia (EL), known as Physta®, is known to increase testosterone levels. Objective: To evaluate the safety and efficacy of Physta® in improving the testosterone levels and quality of life in ageing male subjects. Design: This randomised, double-blind, placebo-controlled study enrolled 105 male subjects aged 50–70 years with a testosterone level 2. The subjects were given either Physta® 100 mg, 200 mg or placebo daily for 12 weeks. The primary endpoints were changes in serum total and free testosterone levels. The secondary endpoints included changes in the level of sex hormone-binding globulin (SHBG), dihydroepiandrosterone (DHEA), glycated haemoglobin (HbA1c), insulin-like growth factor-1 (IGF-1), thyroid function tests (T3, T4, TSH and Free T3) and cortisol. Changes in Ageing Male Symptoms (AMS) score, Fatigue Severity Scale (FSS) score and muscle strength are other secondary endpoints. The safety of the intervention products was measured by complete blood count, lipid profile, liver and renal function tests. Results: There was a significant increase in the total testosterone levels at week 12 (P < 0.05) in the Physta® 100 mg group and at weeks 4 (P < 0.05), 8 (P < 0.01) and 12 (P < 0.001) in the Physta® 200 mg group compared to placebo. No significant between-group differences in free testosterone levels were observed but a significant within-group increase occurred at weeks 4 (P < 0.01), 8 (P < 0.001) and 12 (P < 0.001) in the Physta®100 mg group and at weeks 2 (P < 0.01), 4 (P < 0.01), 8 (P < 0.001) and 12 (P < 0.001) in the Physta® 200 mg group. The AMS and FSS showed significant reduction (P < 0.001) in total scores at all time-points within- and between-group in both Physta® groups. DHEA levels significantly increased (P < 0.05) within-group in both Physta® groups from week 2 onwards. Cortisol levels significantly (P < 0.01) decreased in the Physta® 200 mg group, while muscle strength significantly (P < 0.001) increased in both Physta® groups at week 12 in the within-group comparison. There were no significant changes in SHBG. No safety related clinically relevant changes were observed. Conclusion: Supplementation of Physta® at 200 mg was able to increase the serum total testosterone, reduce fatigue and improve the quality of life in ageing men within 2 weeks’ time. Trial registration: This clinical study has been registered in ctri.nic.in (CTRI/2019/03/017959).Keywords
This publication has 64 references indexed in Scilit:
- Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjectsJournal of the International Society of Sports Nutrition, 2013
- Randomized Clinical Trial on the Use of PHYSTA Freeze-Dried Water Extract ofEurycoma longifoliafor the Improvement of Quality of Life and Sexual Well-Being in MenEvidence-Based Complementary and Alternative Medicine, 2012
- The Comparison of the Aging Male Symptoms (AMS) Scale and Androgen Deficiency in the Aging Male (ADAM) Questionnaire to Detect Androgen Deficiency in Middle‐Aged MenJournal of Andrology, 2012
- Tongkat Ali (Eurycoma longifolia Jack): A review on its ethnobotany and pharmacological importanceFitoterapia, 2010
- Fifty‐ two—Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma TestosteroneJournal of Andrology, 2009
- The endocrine system and ageingThe Journal of Pathology, 2007
- Calculation of Bioavailable and Free Testosterone in Men: A Comparison of 5 Published AlgorithmsClinical Chemistry, 2006
- Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidismActa Endocrinologica, 2005
- Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiencyThe Aging Male, 2003
- A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's diseaseThe Aging Male, 2003